Aravive Inc (ARAV)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Gail F. McIntyre
Employees:
20
RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098
936-355-1910

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum-resistant recurrent ovarian cancer. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the signaling pathway.

Data derived from most recent annual or quarterly report
Market Cap 25.827 Million Shares Outstanding28.825 Million Avg 30-day Volume 89.382 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.66
Price to Revenue19.5042 Debt to Equity0.1338 EBITDA-28.969 Million
Price to Book Value2.3074 Operating Margin-541.4952000000001 Enterprise Value56.772 Million
Current Ratio6.52 EPS Growth-0.229 Quick Ratio6.399
1 Yr BETA 1.0342 52-week High/Low 4.4 / 0.8 Profit Margin-537.2559
Operating Cash Flow Growth28.7571 Altman Z-Score-7.4583 Free Cash Flow to Firm -3.739 Million
View SEC Filings from ARAV instead.

View recent insider trading info

Funds Holding ARAV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARAV

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-26:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-11:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-04:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-01:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GELLER ROBERT B. CHIEF MEDICAL OFFICER

    • Officer
    0 2022-07-01 2

    HOWARD RUDY CHIEF FINANCIAL OFFICER

    • Officer
    0 2022-06-03 2

    ESHELMAN FREDRIC N EXECUTIVE CHAIRMAN OF BOARD

    ESHELMAN VENTURES, LLC

    • Officer
    • Director
    • 10% Owner
    • SEE FOOTNOTE (1)
    9,211,769 2022-04-01 4

    DOVE LEONARD SCOTT CHIEF OPERATING OFFICER

    • Officer
    200,000 2022-03-21 2

    MCINTYRE GAIL FRANCES CEO AND PRESIDENT

    • Officer
    • Director
    425,000 2022-01-24 1

    SHAH VINAY CHIEF FINANCIAL OFFICER

    • Officer
    175,000 2022-01-24 1

    RANGWALA RESHMA CHIEF MEDICAL OFFICER

    • Officer
    175,000 2022-01-24 1

    GIACCIA AMATO

    • Director
    941,880 2021-12-03 3

    ROGERS MICHAEL W

    • Director
    22,812 2021-09-10 1

    KIRK SIGURD

    • Director
    22,812 2021-09-10 1

    HO PETER TAI-CHING

    • Director
    22,812 2021-09-10 1

    HOHNEKER JOHN

    • Director
    22,812 2021-09-10 1

    ZHANG ERIC

    • Director
    22,812 2021-09-10 1

    TABIBIAZAR RAYMOND

    • Director
    0 2020-09-14 0

    HOFFMAN ROBERT

    • FORMER DIRECTOR
    No longer subject to file 2020-04-08 0

    AKKARAJU SRINIVAS

    • FORMER DIRECTOR
    No longer subject to file 2020-04-08 0

    SHEPARD JAY

    • FORMER DIRECTOR
    No longer subject to file 2020-04-08 0

    HEMRAJANI REKHA

    • SEE REMARKS
    No longer subject to file 2020-04-08 0

    MALIK SHAHZAD

    • Director
    0 2019-09-12 0

    HAAS KEVIN VP, FINANCE AND PAO

    • Officer
    0 2019-02-28 0

    GIACCIA AMATO

    GIACCIA AMATO

    • Director
    • 10% Owner
    0 2019-01-03 3

    SHEPARD JAY PRESIDENT AND CEO

    SHEPARD JAY PRESIDENT AND CEO

    • Officer
    • Director
    84,113 2018-12-21 0

    WESTBERG PAUL SVP AND CHIEF BUSINESS OFFICER

    • Officer
    225,124 2018-06-15 0

    STOUT JAY S SVP, TECHNICAL OPERATIONS

    • Officer
    185,646 2018-04-24 0

    WOODY TRACY M CHIEF COMMERCIAL OFFICER

    • Officer
    215,755 2018-03-23 0

    WARD SHANE SVP AND GENERAL COUNSEL

    • Officer
    201,556 2018-02-08 0

    DOBMEIER ERIC

    • Director
    18,160 2017-12-20 0

    GREER R SCOTT

    • Director
    44,380 2017-12-20 0

    JENNINGS EDMON R

    • Director
    22,380 2017-12-20 0

    SUN ANTHONY Y

    • Director
    23,880 2017-12-20 0

    VARIAN JOHN

    • Director
    22,280 2017-12-20 0

    GUT ROBERT CHIEF MEDICAL OFFICER

    • Officer
    227,300 2017-12-20 0

    HISLOP COLIN CHIEF MEDICAL OFFICER

    • Officer
    23,833 2017-10-19 0

    BRUMM JOSHUA T COO AND CFO

    • Officer
    201,269 2017-10-19 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    No longer subject to file 2017-09-21 0

    CLELAND JEFFREY L PRESIDENT AND CEO

    • Officer
    • Director
    121,548 2015-04-14 0

    NEW LEAF VENTURES II, L.P.

    NEW LEAF VENTURE ASSOCIATES II, L.P.

    NEW LEAF VENTURE MANAGEMENT II, L.L.C.

    CHAMBON PHILIPPE O.

    HUNT RONALD

    LATHI VIJAY K

    DELAGARDELLE JEANI

    RATCLIFFE LIAM

    • 10% Owner
    No longer subject to file 2014-12-18 0

    INDEX VENTURES IV (JERSEY) LP

    INDEX VENTURES IV PARALLEL ENTREPRENEUR FUND (JERSEY) LP

    YUCCA (JERSEY) SLP

    • 10% Owner
    19,161 2014-11-24 0

    NEW LEAF VENTURES II, L.P.

    NEW LEAF VENTURE ASSOCIATES II, L.P.

    NEW LEAF VENTURE MANAGEMENT II, L.L.C.

    CHAMBON PHILIPPE O.

    NIEDEL JAMES

    HUNT RONALD

    LATHI VIJAY K

    DELAGARDELLE JEANI

    RATCLIFFE LIAM

    • 10% Owner
    3,359,374 2014-09-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    GELLER ROBERT B. - Officer CHIEF MEDICAL OFFICER

    2022-07-05 12:06:46 -0400 2022-07-01 A 200,000 a 200,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ARAVIVE INC ARAV 2022-08-12 22:15:03 UTC 1.2968 1.0232 350000
    ARAVIVE INC ARAV 2022-08-12 21:45:04 UTC 1.2968 1.0232 350000
    ARAVIVE INC ARAV 2022-08-12 21:15:04 UTC 1.2968 1.0232 350000
    ARAVIVE INC ARAV 2022-08-12 20:45:04 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 20:15:05 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 19:45:03 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 19:15:05 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 18:45:03 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 18:15:04 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 17:45:04 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 17:15:05 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 16:45:04 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 16:15:04 UTC 1.2969 1.0231 350000
    ARAVIVE INC ARAV 2022-08-12 15:45:04 UTC 1.2969 1.0231 300000
    ARAVIVE INC ARAV 2022-08-12 15:15:05 UTC 1.2969 1.0231 300000
    ARAVIVE INC ARAV 2022-08-12 14:45:04 UTC 1.2969 1.0231 300000
    ARAVIVE INC ARAV 2022-08-12 14:15:05 UTC 1.2969 1.0231 300000
    ARAVIVE INC ARAV 2022-08-12 13:45:04 UTC 1.2969 1.0231 300000
    ARAVIVE INC ARAV 2022-08-12 13:15:04 UTC 1.2969 1.0231 300000
    ARAVIVE INC ARAV 2022-08-12 12:45:04 UTC 1.2969 1.0231 300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments